SecBot SecBot
SC 13G ·Filed Nov 13, 2026

MTRI

InMed Pharmaceuticals Inc.
NEUTRAL
Impact 4/10
Horizonimmediate Processed3d 11h ago SEC0001172661-26-005030
Passive investor 5%+ stake
Actionable Insight • Neutral

Deep Track's new 5.64% passive stake, combined with ADAR1 Capital's 17.2% position, means over 22% of shares are held by two passive filers post-merger. Monitor for any future 13D conversion or additional insider buying, but the passive certification suggests no near-term activist intent.

DirectionNeutral
Confidencehigh
Horizonimmediate

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Deep Track Capital, LP filed a Schedule 13G disclosing a 5.64% passive stake in Mentari Therapeutics (formerly InMed Pharmaceuticals) as of November 13, 2026, representing 2,977,478 common shares. This is a new position following the company's reverse merger with Mentari on November 6, 2026, and adds to the existing passive ownership by ADAR1 Capital (17.2%) and prior filer Ikarian Capital.

Key Financial Metrics

Stake
5.64%
Investor
Deep Track Capital, LP
Investor Type
hedge fund

Key Facts

  • Deep Track Capital, LP disclosed a 5.64% passive stake in Mentari Therapeutics (formerly InMed Pharmaceuticals) as of November 13, 2026
  • The stake consists of 2,977,478 common shares, held across Deep Track Biotechnology Master Fund, Ltd. (2,214,135 shares) and Deep Track Special Opportunities Fund, LP (763,343 shares)
  • The filing certifies passive intent under Rule 13d-1(c), with no purpose of changing or influencing control
  • This is a new position filed 7 days after the company's reverse merger with Mentari on November 6, 2026
  • The issuer reported 52,813,914 common shares outstanding as of November 10, 2026
  • David Kroin is the control person for Deep Track Capital, LP

Financial Impact

5.64% passive stake valued at approximately $508K based on $9M market cap

ownership concentration

Risk Factors

  • Passive stake certification could be converted to active (13D) if Deep Track changes intent, though no indication in this filing
  • Small market cap ($9M) and high volatility (10% normal daily move) make the stock susceptible to large price swings on low volume

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0001172661-26-005030
Document: 0001172661-26-005030-index.html0001172661-26-005030
Document: 0001172661-26-005030.txt0001172661-26-005030

US Market Status

Market Closed · Opens in 6h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026